Preventing cervical cancer

Share This Post

The FDA says that although cervical cancer kills about 4,000 women in the United States each year, most cervical cancers are preventable. Moreover, if the diagnosis is timely, cervical cancer can be cured, and the FDA has approved three vaccines (2, 4 and 9) to prevent cervical cancer.

Cervical cancer is usually formed in the lower part of the cervix or uterus adjacent to the vagina. It is caused by human papillomavirus (HPV), but not all people who carry the HPV virus will get cervical cancer. Cervical cancer has few symptoms, but it can be detected by conventional Pap smear, which is a cervical smear. This test requires taking some cells from the cervix, and then the laboratory checks whether these cells have abnormal cancerous changes. sign. If the Pap smear test results are abnormal, further examinations must be performed, including HPV examinations. If these two tests can be done at the same time, the false negative rate will be greatly reduced.

According to the FDA, there are more than 100 types of HPV, some of which are non-pathogenic. The HPV test detects those types of HPV that are more likely to cause cancer. Some women also need cervical biopsies if necessary. The HPV vaccine does not treat cervical cancer, but it can play a good role in preventing cervical cancer caused by high-risk types of HPV. Among them, cervical cancers caused by HPV types 16 and 18 account for 70% of the total. Gardsey 9 is the highest-priced preventive vaccine that can prevent cervical cancer caused by 9 types of HPV and provide comprehensive protection. People are best vaccinated before getting HPV to get full protection.

These vaccines are only preventive, and they work on the same principle as other vaccines that prevent viruses and bacterial diseases: they encourage the body to produce antibodies to viruses. However, remind female friends that regardless of whether they have been vaccinated, they should have regular Pap smears because it is extremely important to detect cervical cancer and precancerous lesions.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy